BioSpace News Archive

- The LIFE-BTK trial will evaluate the company’s new drug-eluting resorbable scaffold (DRS), known as the Esprit BTK System, for the treatment of blocked arteries below-the-knee (BTK) - Esprit BTK was granted breakthrough device designation by the U.S. FDA - There are no stents or drug-coated balloons currently approved for use below the knee in the U.S. [03-September-2020]

Deep Lens announced that Kamala Maddali, DVM, PhD, has been appointed to the Society for Clinical Research Sites Oncology Program Board.

Boundless Bio , a company developing innovative new therapies directed to extrachromosomal DNA (ecDNA) in aggressive cancers, today announced it will present a corporate overview at Citi’s 15th Annual BioPharma Virtual Conference. Date: Tuesday, September 8th Time: 4:40 p.m. EDT Presenter: Zachary Hornby, President and Chief Executive Officer of Boundless Bio About Boundless Bio Boundless Bio is a

Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe COVID-19. The panel session, entitled Lessons from Bergamo: Discoveries in Treating Critically-ill COVID-19 Patients , was held on September 2, 2020 and included i

Huami Corp. (NYSE: HMI) today announced that it will be participating in the Wells Fargo Securities 3 rd Annual Virtual Consumer Conference. COO Mike Yeung and IRO Brad Samson will be conducting one-on-one meetings on September 16 and 17. Interested investors can contact their Wells Fargo salesperson for availability. Huami’s miss

Exactech , a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery, announced today that, in the largest study of its kind, Exactech’s Equinoxe® shoulder system demonstra

POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that it will report and present its financial results for the first half 2020 on Tuesday, September 15, 2020. The management team will host a conference call on September 15, 2020 in Engl

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), today announced it will release its financial results for the second quarter of 2020 after market close on Thursday, September 17, 2020. In conjunction with the release, Acutus will host a conference call and webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss its financial results and recent highlights. Interested parties may access the live call via telephone by dialing (8

On August 4 th , 2020 Premier Health of America Inc. (formerly known as Physinorth Acquisition Corporation Inc.) (TSXV: PHA) (the “ Corporation ” or “ Premier Health ”), a leading Canadian Healthtech company, announced that on August 3 rd , 2020, it had entered into a share purchase agreement (the “ SPA ”) to acquire 100% of the issued and outstanding shares of 9104-8306 Québec Inc. d.b.a Code Bleu Placement en Santé (“ Code Bleu ”), (the “ Transact

CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, provides an update on progress for the U.S. manufacturing of Berubicin, the Company’s lead drug candidate, in preparation for upcoming clinical trials.